Elasmogen, which is part of the Deepbridge Life Sciences EIS portfolio, have announced a collaboriation with Intract Pharma Limited London, to discover and develop novel orally-delivered protein therapeutics, which will incorporate proprietary technologies developed by each company. 

 Caroline Barelle, CEO of Elasmogen commented:

“Achieving oral delivery of our soloMER products is a key differentiator for our technology and I am delighted that following very encouraging proof of concept studies with Intract’s Soteria technology we can now announce this extended and accelerating collaboration.”

To find out more about Elasmogen please click here.